Oral News and Research

RSS

Amgen presents data from several romosozumab and Prolia at ASBMR 2013 Annual Meeting

Amgen today announced that it will present data from several romosozumab and Prolia® (denosumab) studies at the American Society for Bone and Mineral Research (ASBMR) 2013 Annual Meeting in Baltimore from Oct. 4-7, 2013.

5 Oct 2013

High-dose statins could have added benefit of reducing gum inflammation

The use of high-dose statins to lower cholesterol in heart disease patients appears to have the added benefit of reducing gum inflammation, according to research published in the Journal of the American College of Cardiology.

4 Oct 2013

Scientists identify chemical agents that block flu virus's ability to replicate itself in cell culture

A new way to attack flu viruses is taking shape in laboratories at Rutgers University, where scientists have identified chemical agents that block the virus's ability to replicate itself in cell culture.

4 Oct 2013

Researchers launch phase II clinical trial of rectal microbicide to prevent HIV infections

Taking an important step toward the development of a product to prevent HIV infections associated with unprotected anal sex, researchers today announced the launch of a global Phase II clinical trial of a potential rectal microbicide.

3 Oct 2013

Data from Flexion Therapeutics' FX006 Phase 2b trial for OA to be presented at ACR/ARHP meeing

Flexion Therapeutics, Inc. announced today that new data from a Phase 2b dose-ranging trial of the company's lead compound, FX006, in osteoarthritis has been accepted for an oral presentation at the 2013 Annual Scientific Meeting of the American College of Rheumatology and the Association of Rheumatology Health Professionals.

2 Oct 2013

Klox Biophotonic System gets approval in Canada for treatment of acne vulgaris

KLOX Technologies Inc. announces the approval in Canada of the Klox Biophotonic System (also known as the Lumigel Cleanse System) for the treatment of acne vulgaris after receiving this week a Medical Device License from the Therapeutic Products Directorate - Medical Devices Bureau of Health Canada

2 Oct 2013

Data analyses from Brisdelle Phase 3 pivotal trials to be showcased at NAMS' meeting

Noven Pharmaceuticals, Inc., today announced that 11 presentations, featuring data analyses from its Phase 3 pivotal trials that supported the recent U.S. Food and Drug Administration approval of Brisdelle (paroxetine capsules, 7.5 mg/day) for the treatment of moderate to severe vasomotor symptoms associated with menopause, will be showcased at the 2013 Annual Meeting of The North American Menopause Society in Dallas on Oct. 9-10.

2 Oct 2013

Epigenetic Markers Found For Head And Neck Cancers

...

2 Oct 2013

Over-the-counter ibuprofen appears to be safest alternative for reducing post-operative pain

You may be able to eat all of the ice cream you want after having your tonsils removed, but researchers at Henry Ford Hospital in Detroit say you don't necessarily need a prescription to reduce post-operative pain -- an over-the-counter pain-reliever is just as effective.

2 Oct 2013

Researchers compare cardiovascular safety of two commonly used oral estrogen medications

The oral hormone therapy conjugated equine estrogens, which is used by women to relieve menopause symptoms, appears to be associated with increased risk for venous thrombosis (VT, blood clots) and possibly myocardial infarction (heart attack), but not ischemic stroke risk, when compared with the hormone therapy oral estradiol, according to a study published by JAMA Internal Medicine, a JAMA Network publication.

1 Oct 2013

Olympic athletes lose to poor dental health

Olympic athletes appear to be at an increased risk of poor dental health, an outcome that may negatively impact on their well being and also on their ability to train and perform, research shows.

1 Oct 2013

Unique DNA markings on certain genes may 'predict' risk of developing head and neck cancer

Unique DNA markings on certain genes may "predict" the risk of developing head and neck cancer, according to new research led by Queen Mary University of London.

1 Oct 2013

Biochemists discover promising vitamin D-based treatment that halts or reverse MS

A diagnosis of multiple sclerosis (MS) is a hard lot. Patients typically get the diagnosis around age 30 after experiencing a series of neurological problems such as blurry vision, wobbly gait or a numb foot. From there, this neurodegenerative disease follows an unforgiving course.

1 Oct 2013

Mylan Pharmaceuticals launches Voriconazole for Oral Suspension

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Voriconazole for Oral Suspension, 40 mg/mL, which is the first generic version of Pfizer's VFEND for Oral Suspension.

30 Sep 2013

Women with recurrent ovarian cancer survive longer after treatment with cediranib

Women with ovarian cancer that has recurred after chemotherapy have survived for longer after treatment with a biological therapy called cediranib, according to new results to be presented today (Monday) at the 2013 European Cancer Congress.

30 Sep 2013

Department of Defense backs tissue-engineering research for soldiers, civilians

A $75 million Department of Defense grant to improve technologies to treat soldiers injured on the battlefield and advance care for the public will involve bioengineers at Rice University and the University of Texas Health Science Center at Houston.

30 Sep 2013

Biochemists discover promising vitamin D-based treatment that can halt MS

A diagnosis of multiple sclerosis is a hard lot. Patients typically get the diagnosis around age 30 after experiencing a series of neurological problems such as blurry vision, wobbly gait or a numb foot. From there, this neurodegenerative disease follows an unforgiving course.

29 Sep 2013

Intestinal mucus potentially improves life of people suffering from inflammatory bowel disease

Researchers at Institut Hospital del Mar d'Investigacions M-diques (IMIM) in Barcelona, in collaboration with the Icahn School of Medicine at Mount Sinai in New York and other U.S. Institutions, have found that intestinal mucus not only acts as a physical barrier against commensal bacteria and dietary antigens, but also prevents the onset of inflammatory reactions against these agents.

27 Sep 2013

Icotinib matches gefitinib in NSCLC second or third line

Icotinib has been found to be noninferior to gefitinib in patients with non-small-cell lung cancer, according to reports from the phase III Chinese double-blind ICOGEN study.

26 Sep 2013

Chronic bronchitis linked to poor asthma outcomes

Researchers have found that chronic bronchitis is associated with worse clinical outcomes in asthma, particularly among smokers.

26 Sep 2013

Oral News and Research

Amgen presents data from several romosozumab and Prolia at ASBMR 2013 Annual Meeting

High-dose statins could have added benefit of reducing gum inflammation

Scientists identify chemical agents that block flu virus's ability to replicate itself in cell culture

Researchers launch phase II clinical trial of rectal microbicide to prevent HIV infections

Data from Flexion Therapeutics' FX006 Phase 2b trial for OA to be presented at ACR/ARHP meeing

Klox Biophotonic System gets approval in Canada for treatment of acne vulgaris

Data analyses from Brisdelle Phase 3 pivotal trials to be showcased at NAMS' meeting

Epigenetic Markers Found For Head And Neck Cancers

Over-the-counter ibuprofen appears to be safest alternative for reducing post-operative pain

Researchers compare cardiovascular safety of two commonly used oral estrogen medications

Olympic athletes lose to poor dental health

Unique DNA markings on certain genes may 'predict' risk of developing head and neck cancer

Biochemists discover promising vitamin D-based treatment that halts or reverse MS

Mylan Pharmaceuticals launches Voriconazole for Oral Suspension

Women with recurrent ovarian cancer survive longer after treatment with cediranib

Department of Defense backs tissue-engineering research for soldiers, civilians

Biochemists discover promising vitamin D-based treatment that can halt MS

Intestinal mucus potentially improves life of people suffering from inflammatory bowel disease

Icotinib matches gefitinib in NSCLC second or third line

Chronic bronchitis linked to poor asthma outcomes

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News